What is HC Wainwright’s Estimate for FHTX FY2026 Earnings?

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – HC Wainwright increased their FY2026 earnings per share estimates for shares of Foghorn Therapeutics in a note issued to investors on Thursday, March 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($1.14) per share for the year, up from their prior estimate of ($1.16). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Foghorn Therapeutics’ FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($0.71) EPS and FY2029 earnings at ($0.17) EPS.

Foghorn Therapeutics (NASDAQ:FHTX) last released its quarterly earnings results on Wednesday, March 11th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The business had revenue of $9.25 million during the quarter, compared to the consensus estimate of $9.50 million.

Several other research analysts also recently weighed in on FHTX. BTIG Research started coverage on shares of Foghorn Therapeutics in a research note on Thursday, December 18th. They issued a “buy” rating and a $11.00 target price for the company. Wall Street Zen cut shares of Foghorn Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Jefferies Financial Group reiterated a “buy” rating on shares of Foghorn Therapeutics in a report on Thursday, March 12th. Stifel Nicolaus assumed coverage on shares of Foghorn Therapeutics in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Foghorn Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.13.

Foghorn Therapeutics Stock Up 1.8%

FHTX opened at $5.06 on Monday. The firm has a market cap of $297.02 million, a P/E ratio of -4.32 and a beta of 3.02. Foghorn Therapeutics has a 52 week low of $2.94 and a 52 week high of $6.95. The business’s fifty day simple moving average is $5.66 and its 200 day simple moving average is $5.05.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brummer Multi Strategy AB acquired a new stake in Foghorn Therapeutics during the fourth quarter worth $25,000. Russell Investments Group Ltd. increased its holdings in Foghorn Therapeutics by 13,755.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 5,542 shares of the company’s stock valued at $27,000 after buying an additional 5,502 shares during the period. Evelyn Partners Asset Management Ltd acquired a new position in shares of Foghorn Therapeutics in the 2nd quarter valued at $33,000. BNP Paribas Financial Markets raised its stake in shares of Foghorn Therapeutics by 48.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,103 shares of the company’s stock valued at $35,000 after buying an additional 2,305 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Foghorn Therapeutics by 136.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,213 shares of the company’s stock worth $43,000 after acquiring an additional 5,323 shares during the period. 61.55% of the stock is owned by institutional investors.

About Foghorn Therapeutics

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.